Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor

@article{Vitiello2017MitochondrialIA,
  title={Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor},
  author={G. Vitiello and Benjamin D Medina and S. Zeng and T. Bowler and Jennifer Q. Zhang and Jennifer K. Loo and Nesteene J. Param and Mengyuan Liu and Alec J Moral and J. Zhao and F. Rossi and C. Antonescu and V. Balachandran and J. Cross and R. DeMatteo},
  journal={Clinical Cancer Research},
  year={2017},
  volume={24},
  pages={972 - 984}
}
Purpose: Imatinib dramatically reduces gastrointestinal stromal tumor (GIST) 18F-FDG uptake, providing an early indicator of treatment response. Despite decreased glucose internalization, many GIST cells persist, suggesting that alternative metabolic pathways are used for survival. The role of mitochondria in imatinib-treated GIST is largely unknown. Experimental Design: We quantified the metabolic activity of several human GIST cell lines. We treated human GIST xenografts and genetically… Expand
Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
TLDR
The effects of imatinib treatment on glycolysis and oxidative phosphorylation (OXPHOS), as well as the effect of inhibition of these energy metabolisms on cell viability, are investigated and revealed the potential of targeting the metabolism for GIST therapy. Expand
Tyrosine kinase inhibitor therapy and metabolic re-modeling in papillary thyroid cancer.
TLDR
The data show that metabolic reprogramming in thyroid cancer occurs as a consequence of BRAF-mediated upregulation of HK2 expression that may permit tumour growth with isolated blockade of upstream tyrosine kinase receptors. Expand
Oxidative phosphorylation as a potential therapeutic target for cancer therapy
TLDR
Most of the preclinical data arguing in favor of OXPHOS inhibition have been obtained in xenograft models, in which human cancer cells are implanted in immunodeficient mice, and future studies should elaborate optimal treatment schedules and combination regimens that stimulate—or at least are compatible with—anticancer immune responses for long‐term tumor control. Expand
Translational investigations of novel and current antitumoral therapies in gastrointestinal stromal tumors
TLDR
This translational thesis adds knowledge to new potential targets and novel antitumoral strategies, and increases the understanding of current treatment in GIST. Expand
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways
TLDR
Modulating cancer metabolic pathways through oncogene‐targeting agents may not only restore more favorable conditions for proper lymphocytes activation, but also increase the persistence of memory T cells, thereby improving the efficacy of immune‐surveillance. Expand
Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis
TLDR
It is shown that myoferlin expression in colon cancer lesions is associated with low patient survival and is higher than in non-tumoural adjacent tissue, and the identification of this protein as a suitable new therapeutic target in Colon cancer is identified. Expand
Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia
TLDR
Analysis of the changes in the proteome of KRAS-mutated non-small cell lung cancer (NSCLC) A549 cells in response to trichostatin-A and nicotinamide under normoxia and hypoxia allows us to better understand the metabolic regulations underlying KDACi in NSCLC, taking into account the microenvironment of tumors related to Hypoxia. Expand
Lyn regulates creatine uptake in an imatinib-resistant CML cell line.
TLDR
Investigation of the origin of creatine pools in Myl-R cells suggested that Lyn can affect creatine uptake through Lyn-dependent phosphorylation and regulation of the Na+/K+-ATPase pump activity. Expand
Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer
TLDR
This review summarizes on targeting mitochondria for treatment of chemoresistant ovarian cancer and current state of understanding of the role of mitochondria respiration in ovarian cancer, and that the mitochondrial pathway has recently emerged as critical in sustaining solid tumor progression. Expand
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.
Gastrointestinal stromal tumor (GIST) is the most common human sarcoma, frequently characterized by an oncogenic mutation in the KIT or platelet-derived growth factor receptor alpha (PDGFRA) genes.Expand
...
1
2
3
...

References

SHOWING 1-10 OF 54 REFERENCES
Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
TLDR
Findings contribute to a clearer understanding of the molecular mechanisms involved in the therapeutic benefit of imatinib in GIST and suggest that a drug-mediated decrease in tumor metabolism observed clinically may not entirely reflect therapeutic efficacy of treatment. Expand
Imatinib Mesylate Inhibits Glucose Uptake in Gastrointestinal Stromal Tumor Cells by Downregulation of the Glucose Transporters Recruitment to the Plasma Membrane
TLDR
A rapid decline in glucose uptake following imatinib treatment in GIST cells is dependent on glucose transporter impaired anchorage to the plasma membrane, with the subsequent recruitment of KIT protein. Expand
Nestin regulates proliferation and invasion of gastrointestinal stromal tumor cells by altering mitochondrial dynamics
TLDR
Marked upregulation of nestin expression is found in highly proliferative and invasive gastrointestinal stromal tumor (GIST) specimens and nestin knockdown inhibited the mitochondrial recruitment of Dynamin-related protein1 and induced the change of mitochondrial dynamics. Expand
Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
TLDR
It is found that the immune system contributes substantially to the antitumor effects of imatinib in GIST, and concomitant immunotherapy may further improve outcomes in human cancers treated with targeted agents. Expand
Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors
TLDR
It is suggested that mitochondria may represent an “Achilles heel” for the survival of slowly-proliferating tumor cells and suggest strategies for the development of therapy to target these cell populations. Expand
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
TLDR
It was determined that a subset of human GIST specimens that acquired imatinib resistance acquired expression of activated forms of the MET oncogene, and activation of compensatory MET signaling by KIT inhibition may contribute to tumor resistance. Expand
The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis.
TLDR
Results show that imatinib induces apoptosis in a fraction of GIST cells while, at the same time, a subset of cells undergoes quiescence involving the DREAM complex, a multisubunit complex that has recently been identified as an additional key regulator of quiescent. Expand
Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
TLDR
The small molecule VLX600 is identified as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues and displays tumour growth inhibition in vivo, suggesting that tumours in metabolically compromised microenvironments have a limited ability to respond to decreased mitochondrial function. Expand
New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis
TLDR
The results indicate that FYN or FAK might be potential therapeutic targets to overcome resistance to imatinib in GISTs and showed that the iTRAQ‐based quantitative phosphotyrosine‐focused phosphoproteomic approach is a powerful method for screening phosphiproteins associated with drug resistance. Expand
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression
TLDR
It is pointed out that targeting cancer cell bioenergetics may represent a novel therapeutic avenue in NSCLC, and provides a strong foundation for future clinical trials of metronomic MTAs combined with Akt inhibitors. Expand
...
1
2
3
4
5
...